BTIG raises target for Glaukos stock to USD 205

Published on 10/20/2026 at 20:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glaukos traded within a USD 73.16 to USD 191.62 52-week range. Glaukos stock costs EUR 154.50 on October 20, 2026 at 7:55 p.m. CEST.

Analyst target and reporting date

BTIG raised its Glaukos target from USD 202.00 to USD 205.00 on October 12, 2026.
Glaukos traded within a USD 73.16 to USD 191.62 52-week range on October 20, 2026.
Glaukos stock was trading at EUR 154.50 at Lang & Schwarz on October 20, 2026 at 7:55 p.m. CEST.
Glaukos is scheduled to report third-quarter results after the market close on October 28, 2026.

GKOS, US3773221029, Illustration mit AI erstellt.

Glaukos Corporation (US3773221029) remains in focus after BTIG analyst Ryan Zimmerman raised the firm's price target from USD 202.00 to USD 205.00 on October 12, 2026, while keeping a Buy rating, as Markets Insider reported. The new target stood 18.11 percent above the USD 173.56 NYSE price at the October 20, 2026 afternoon quote. Glaukos was trading at EUR 154.50 at Lang & Schwarz on October 20, 2026 at 7:55 p.m. CEST.

Stock remains below its yearly high

Glaukos traded within a USD 73.16 to USD 191.62 52-week range on October 20, 2026. The USD 173.56 NYSE price was 9.43 percent below the 52-week high and 137.23 percent above the low, placing the shares in the upper part of the annual band.

Quarterly growth sets the backdrop

In the second quarter of 2026, Glaukos reported consolidated net sales of USD 185.61 million, up 50.00 percent from the year-earlier quarter. The company also reported a gross margin of about 85.00 percent and iDose TR sales of about USD 74.00 million, according to the Yahoo Finance transcript dated July 29, 2026. The company said the quarter supported full-year sales guidance of USD 680.00 million to USD 700.00 million, compared with the previous USD 620.00 million to USD 635.00 million range.

October 28 is the next date

Glaukos is scheduled to report third-quarter 2026 results after the market close on October 28, 2026, according to Simply Wall St. That report will give investors a fresh measure of whether the strong second-quarter sales pace is carrying into the transition around Epioxa's permanent reimbursement code.

Mizuho said on October 13, 2026 that procedure-volume headwinds related to the Affordable Care Act and Medicaid contraction remained a consideration while it raised its target to USD 190.00 from USD 185.00, as Markets Insider reported.

Euro quote after the Xetra close

At the NYSE, Glaukos was trading at USD 173.56 on October 20, 2026 at 2:00 p.m. ET, while its market capitalization stood at USD 10.2 billion. The euro quote from Lang & Schwarz was EUR 154.50 at 7:55 p.m. CEST on October 20, 2026.

The further course of trading is shown by the continuously updated real-time quote of Glaukos stock.